Nanogen Inc and American Bio Medica Corp (AMBC) have entered into a supply agreement in which ABMC will sell its rapid drugs of abuse (DOA) tests to Nanogen. Nanogen will market the tests under its own Tox STATus™ brand name to customers in hospital-related markets using its existing sales force and distribution network.
The immunoassay DOA tests, which can be used to detect up to 15 commonly abused substances including cocaine, methamphetamine and THC, are FDA-cleared and CE marked.
Nanogen currently manufactures and markets its Cardiac STATus™ immunoassay tests for rapid emergency room detection of heart attacks on a global basis. The ABMC-manufactured tests can deliver results using Nanogen’s portable hand-held I-Lynx reader.
 Nanogen expects to begin distribution of the DOA rapid tests before the end of the year.
“The drugs of abuse products supplied by ABMC expand our ability to meet the point of care needs of our current customers and they will also help to attract additional customers,” says Howard Birndorf, Nanogen’s chairman and CEO. “We examined a number of potential partners for penetrating the growing DOA diagnostic market, and we are very pleased with the performance of the ABMC tests.”